^
    Back
    Association details:
    Biomarker:MGMT underexpression
    Cancer:Colorectal Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    temozolomide (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Res Commun
    Title:

    Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

    Published date:
    06/28/2023
    Excerpt:
    Patients with advanced colorectal cancer...received TMZ 75 mg/m2 days 1-7 with olaparib 150 mg twice daily every 21 days….Antitumor activity seen in patients with low MGMT protein expression, supports MGMT protein as a predictor of alkylator sensitivity.
    DOI:
    https://doi.org/10.1158/2767-9764.CRC-23-0045